







an Open Access Journal by MDPI

Hepatocellular Cancer Treatment

Guest Editor:

Prof. Dr. Renuka Iyer

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

Deadline for manuscript submissions:

closed (15 July 2019)

Message from the Guest Editor

Dear Colleagues,

Progress in hepatocellular cancer has been remarkable in the last year after a decade of unsuccessful trials. Besides great strides in treating hepatitis C, we now have a number of molecularlytargeted drugs and immunotherapies, and the best treatment option and sequence for advanced patients is evolving. Early detection, optimal selection of candidates for surgery, and liver-directed therapies remain challenging. This Special Issue will discuss important basic science developments in our understanding of liver cancer biology; innovations in the treatment of localized disease; and novel therapeutics, especially immunotherapy agents and upcoming trials that may impact the treatment of hepatocellular cancer in the years to come.

Prof. Dr. Renuka Iyer *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us